Glucotrack, Inc.
For the period ended Dec 31, 2024. Filed Apr 28, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Dec 31, 2024 · Filed Apr 28, 2025
Contents
PROXY STATEMENT
PROXY STATEMENT FOR THE
2025 ANNUAL MEETING OF STOCKHOLDERS
2025 Annual Meeting of Stockholders
This proxy statement and associated proxy card are furnished in connection with the solicitation of proxies to be voted at the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Glucotrack, Inc. (“we,” “us,” the “Company” or “Glucotrack”), which will be held on Thursday, May 22, 2025 at 12:00 p.m. Eastern Time, virtually via the Internet at*www.virtualshareholdermeeting.com/GCTK2025.*You will need to enter the 16-digit control number received with your proxy card to enter the Annual Meeting via the online web portal.
By visiting this website, you may attend the Annual Meeting virtually online, vote your shares electronically and submit your questions to management during the Annual Meeting.
This proxy statement and our Annual Report on Form 10-K for the year ended December 31, 2024 (the “Annual Report”) are available to stockholders at*www.virtualshareholdermeeting.com/GCTK2025.*The proxy statement for the Annual Meeting (the “proxy statement”) contains important information about the Annual Meeting and each of the proposals. Whether or not you plan to attend the Annual Meeting, the Company urges you to read this material carefully and vote your shares.
This proxy statement for the Annual Meeting is dated April 28, 2025 and is being distributed or made available to stockholders on or about that date.
Proposals to be Voted on at the Annual Meeting
The following matters are scheduled to be voted on at the Annual Meeting:
| ● | Proposal 1: To elect five directors, each to serve until the 2026 annual meeting of stockholders and until his or her successor is duly elected and qualified; |
| ● | Proposal 2: To ratify the appointment of Fahn Kanne & Co. Grant Thornton Israel as our independent registered public accounting firm for the year ending December 31, 2025; |
| ● | Proposal 3: To approve an amendment to the Company’s certificate of incorporation (as amended, the “Certificate of Incorporation”) to effect a reverse stock split of the Company’s common stock par value $0.001 per share (“Common Stock”) at a ratio not to exceed one-for-one hundred; and |
| ● | Proposal 4: To approve an amendment to the Glucotrack, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) to increase the aggregate number of shares of Common Stock available for issuance under the 2024 Plan to 7,500,000 shares of Common Stock. |
Our “named executive officers” in this proxy statement, as determined under applicable SEC rules for smaller reporting companies like the Company is Paul V. Goode, our Chief Executive Officer.
No cumulative voting rights are authorized, and appraisal or dissenters’ rights are not applicable to these matters.
Questions and Answers about the Annual Meeting
Please see “Questions and Answers about the Annual Meeting” beginning on page 40 for important information about the proxy materials, voting, the Annual Meeting, Company documents, communications and the deadlines to submit stockholders’ proposals and director nominees for the 2025 Annual Meeting.
If you have any questions, require any assistance with voting your shares or need additional copies of this proxy statement or voting materials, please contact:
Glucotrack, Inc.
Corporate Secretary
Rutherford, NJ 07070
Telephone: (201) 842-7715
MATTERS TO BE VOTED UPON BY ALL SHAREHOLDERS
PROPOSAL 1
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.